These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34351305)

  • 21. IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia.
    Song C; Ge Z; Ding Y; Tan BH; Desai D; Gowda K; Amin S; Gowda R; Robertson GP; Yue F; Huang S; Spiegelman V; Payne JL; Reeves ME; Gurel Z; Iyer S; Dhanyamraju PK; Xiang M; Kawasawa YI; Cury NM; Yunes JA; McGrath M; Schramm J; Su R; Yang Y; Zhao Z; Lyu X; Muschen M; Payne KJ; Gowda C; Dovat S
    Blood; 2020 Sep; 136(13):1520-1534. PubMed ID: 32396934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
    Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
    Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitochondrial transcription factor A regulates BCL2L1 gene expression and is a prognostic factor in serous ovarian cancer.
    Kurita T; Izumi H; Kagami S; Kawagoe T; Toki N; Matsuura Y; Hachisuga T; Kohno K
    Cancer Sci; 2012 Feb; 103(2):239-444. PubMed ID: 22098591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1.
    O'Hara SP; Splinter PL; Trussoni CE; Guicciardi ME; Splinter NP; Al Suraih MS; Nasser-Ghodsi N; Stollenwerk D; Gores GJ; LaRusso NF
    J Biol Chem; 2019 Dec; 294(49):18698-18713. PubMed ID: 31659122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppressing the growth of rectal cancer xenografts derived from patient tumors by an adenovector expressing small hairpin RNA targeting Bcl-XL.
    Zhu H; Zhou W; Hu J; Huang Z; Lao W; Huang X; He C
    J Gene Med; 2012 Dec; 14(12):761-8. PubMed ID: 23169477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.
    Turkington RC; Longley DB; Allen WL; Stevenson L; McLaughlin K; Dunne PD; Blayney JK; Salto-Tellez M; Van Schaeybroeck S; Johnston PG
    Cell Death Dis; 2014 Feb; 5(2):e1046. PubMed ID: 24503538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemosensitization of solid tumors by inhibition of Bcl-xL expression using DNAzyme.
    Yu X; Yang L; Cairns MJ; Dass C; Saravolac E; Li X; Sun LQ
    Oncotarget; 2014 Oct; 5(19):9039-48. PubMed ID: 25344863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Ewing Family of Tumors Relies on BCL-2 and BCL-X
    Heisey DAR; Lochmann TL; Floros KV; Coon CM; Powell KM; Jacob S; Calbert ML; Ghotra MS; Stein GT; Maves YK; Smith SC; Benes CH; Leverson JD; Souers AJ; Boikos SA; Faber AC
    Clin Cancer Res; 2019 Mar; 25(5):1664-1675. PubMed ID: 30348635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression.
    Hagenbuchner J; Ausserlechner MJ; Porto V; David R; Meister B; Bodner M; Villunger A; Geiger K; Obexer P
    J Biol Chem; 2010 Mar; 285(10):6904-12. PubMed ID: 20051518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines.
    Yoon H; Choi YL; Song JY; Do I; Kang SY; Ko YH; Song S; Kim BG
    PLoS One; 2014; 9(2):e88587. PubMed ID: 24523919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
    Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
    Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.
    Kulshrestha A; Katara GK; Ginter J; Pamarthy S; Ibrahim SA; Jaiswal MK; Sandulescu C; Periakaruppan R; Dolan J; Gilman-Sachs A; Beaman KD
    Mol Oncol; 2016 Jun; 10(6):789-805. PubMed ID: 26899534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
    Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
    EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.
    Abed MN; Abdullah MI; Richardson A
    J Ovarian Res; 2016 Apr; 9():25. PubMed ID: 27080533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo.
    Lin J; Wu Y; Yang D; Zhao Y
    Oncol Rep; 2013 Aug; 30(2):731-8. PubMed ID: 23708869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.
    Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S
    PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nrf2-induced antiapoptotic Bcl-xL protein enhances cell survival and drug resistance.
    Niture SK; Jaiswal AK
    Free Radic Biol Med; 2013 Apr; 57():119-31. PubMed ID: 23275004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.